1.3 Neurotransmitters, Neuromodulators, and Psychopharmacology

Neurotransmitters, Neuromodulators, and Psychopharmacology

Intercellular communication in the nervous system relies on the release of specialized chemical messengers that diffuse across the synaptic cleft or act diffusely as neuromodulators. A chemical substance is classified as a classic neurotransmitter only if it satisfies four rigorous physiological criteria:

1. It is synthesized within the presynaptic neuron.
2. It is stored within presynaptic vesicles prior to release.
3. It is released in an activity-dependent manner triggered by presynaptic depolarization and calcium influx.
4. When applied experimentally to the postsynaptic cell, it mimics the exact physiological effect of natural presynaptic stimulation, and specific mechanisms exist to terminate its action.

                                [ NEUROTRANSMITTERS ]
                                          │
        ┌─────────────────────────────────┼─────────────────────────────────┐
        ▼                                 ▼                                 ▼
  [ ACETYLCHOLINE ]                [ MONOAMINES ]                   [ AMINO ACIDS ]
  ├── Nicotinic (Ionotropic)       ├── Catecholamines:              ├── Glutamate (Excitatory)
  └── Muscarinic (Metabotropic)    │   ├── Dopamine (DA)            │   ├── AMPA
                                   │   ├── Norepinephrine (NE)      │   └── NMDA (Coincidence Detector)
                                   │   └── Epinephrine (Epi)        └── GABA (Inhibitory)
                                   └── Indolamines:                     ├── GABAA (Cl- channel)
                                       └── Serotonin (5-HT)             └── GABAB (K+ GPCR)

1. Acetylcholine (ACh)

Acetylcholine was the first neurotransmitter discovered, identified by Otto Loewi in 1921 (Vagusstoff) in his classic experiment demonstrating chemical neurotransmission between dual-perfused frog hearts.

• Biosynthesis and Inactivation: Synthesized in the presynaptic cytoplasm from choline and acetyl coenzyme A (acetyl-CoA) via the enzyme choline acetyltransferase (ChAT). Following exocytosis, ACh is rapidly inactivated within the synaptic cleft by acetylcholinesterase (AChE) into acetate and choline; high-affinity choline transporters then pump choline back into the terminal for re-synthesis.
• Receptor Subtypes:
  • Nicotinic ACh Receptors (nAChR): Ionotropic, non-selective cation channels permeable to $Na^+$ and $Ca^{2+}$. Produce rapid, robust depolarizations (fast EPSPs). Found at the somatic neuromuscular junction (NMJ), in autonomic ganglia, and in selected brain regions. Stimulated by nicotine; selectively blocked by curare (producing flaccid paralysis) and alpha-bungarotoxin.
  • Muscarinic ACh Receptors (mAChR): Metabotropic G-protein coupled receptors ($M_1$ through $M_5$). Distributed widely throughout the central nervous system and on parasympathetic target organs. Blocked selectively by atropine (inducing mydriasis and tachycardia) and scopolamine (which impairs working memory and memory encoding).
• Anatomical Pathways and Behavioral Roles:
  • Basal Forebrain: The nucleus basalis of Meynert and medial septal nuclei send widespread cholinergic projections throughout the neocortex and hippocampus, mediating sustained visual attention, wakefulness, and declarative memory encoding.
  • Brainstem: The pedunculopontine and laterodorsal tegmental nuclei project to the thalamus, modulating sleep-wake architecture and triggering REM sleep phenomena.
• Clinical Correlates and Toxins:
  • Alzheimer's Disease: Characterized by early, selective neurodegeneration of cholinergic projection neurons within the nucleus basalis of Meynert, leading to severe cortical acetylcholine depletion. Standard symptomatic pharmacotherapies utilize acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) to prolong synaptic ACh availability.
  • Myasthenia Gravis: An autoimmune neuromuscular disorder in which circulating autoantibodies attack and destroy postsynaptic nicotinic ACh receptors at the neuromuscular junction, producing progressive skeletal muscle weakness and ptosis.
  • Botulinum Toxin (Botox): A bacterial protease that cleaves presynaptic SNARE proteins (SNAP-25), preventing acetylcholine exocytosis and causing flaccid paralysis.
  • Black Widow Spider Venom ($\alpha$-Latrotoxin): Triggers massive, uncontrolled dumping of acetylcholine vesicles into the cleft, causing violent muscular spasms followed by receptor desensitization.

2. Monoamines: Catecholamines and Indolamines

Monoamines possess a single aromatic ring connected to an amino group by a two-carbon chain. They are subdivided into catecholamines (containing a catechol moiety) and indolamines.

The Catecholamine Biosynthetic Pathway

All catecholamines are synthesized through a shared, sequential biochemical pathway originating from the dietary essential amino acid L-tyrosine:

$\text{L-Tyrosine} \xrightarrow[\text{(Rate-Limiting Step)}]{+ \text{ Tyrosine Hydroxylase (TH)}} \text{L-DOPA} \xrightarrow{+ \text{ AADC}} \text{Dopamine} \xrightarrow{+ \text{ DBH}} \text{Norepinephrine} \xrightarrow{+ \text{ PNMT}} \text{Epinephrine}$

1. Tyrosine Hydroxylase (TH): Catalyzes the conversion of tyrosine to L-dihydroxyphenylalanine (L-DOPA). TH is the rate-limiting enzyme of the entire pathway; its activity is regulated by end-product feedback inhibition.
2. Aromatic L-Amino Acid Decarboxylase (AADC / DOPA Decarboxylase): Rapidly converts L-DOPA to Dopamine.
3. Dopamine $\beta$-Hydroxylase (DBH): Located inside synaptic vesicles of noradrenergic neurons; converts Dopamine to Norepinephrine.
4. Phenylethanolamine N-Methyltransferase (PNMT): Located in the adrenal medulla and medullary brainstem; converts Norepinephrine to Epinephrine.

Dopamine (DA): Pathways and Receptor Subtypes

Dopamine acts primarily as a neuromodulator via five metabotropic receptor subtypes categorized into two families:

• $D_1$-like Family ($D_1, D_5$): Coupled to $G_s/G_{olf}$, stimulating adenylyl cyclase, elevating cyclic AMP (cAMP), and increasing protein kinase A (PKA) activity.
• $D_2$-like Family ($D_2, D_3, D_4$): Coupled to $G_i/G_o$, inhibiting adenylyl cyclase, lowering cAMP, opening potassium channels, and acting as inhibitory presynaptic autoreceptors that suppress further dopamine release.

                               [ DOPAMINERGIC PATHWAYS ]
                                           │
        ┌───────────────────────────┬──────┴────────────────────┬───────────────────────────┐
        ▼                           ▼                           ▼                           ▼
  [ MESOLIMBIC ]             [ MESOCORTICAL ]            [ NIGROSTRIATAL ]         [ TUBEROINFUNDIBULAR ]
  VTA ──> N. Accumbens       VTA ──> Prefrontal Cortex   S. Nigra ──> Striatum     Hypothalamus ──> Pituitary
  - Incentive salience       - Executive function        - Motor coordination      - Tonically inhibits
  - Positive symptoms        - Negative/cognitive        - Parkinson's deficits      prolactin secretion
    of schizophrenia           symptoms of schiz.        - Antipsychotic EPS       - Blockade causes
  - Addiction / reward       - Working memory            - Tardive dyskinesia        hyperprolactinemia

1. Mesolimbic Pathway: Originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens, olfactory tubercle, and amygdala. Mediates incentive salience ("wanting" rather than "liking"), reinforcement learning, and motivation. All addictive drugs (cocaine, amphetamines, nicotine, opioids, alcohol) converge to elevate extracellular dopamine within this pathway. Hyperactivity of the mesolimbic pathway underlies the positive symptoms of schizophrenia (hallucinations, delusions).
2. Mesocortical Pathway: Originates in the VTA and projects to the prefrontal cortex. Governs working memory, cognitive flexibility, and emotional expression. Hypoactivity of mesocortical projections contributes to the negative symptoms (avolition, flat affect, anhedonia) and cognitive deficits of schizophrenia.
3. Nigrostriatal Pathway: Originates in the substantia nigra pars compacta ($SNc$) and projects to the dorsal striatum (caudate and putamen), containing roughly 80% of total brain dopamine. Degeneration of this tract produces Parkinson's disease. Conversely, therapeutic antagonism of $D_2$ receptors in this pathway by first-generation antipsychotics produces extrapyramidal symptoms (EPS) and, following chronic treatment, tardive dyskinesia.
4. Tuberoinfundibular Pathway: Originates in the arcuate nucleus of the hypothalamus and projects via the median eminence to the anterior pituitary gland, where dopamine acts as a neurohormone to tonically inhibit prolactin secretion. Antipsychotic drugs that block $D_2$ receptors disinhibit prolactin, leading to hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction).

Norepinephrine and Epinephrine

• Norepinephrine (NE / Noradrenaline):
  • Anatomy: Synthesized primarily within the locus coeruleus in the dorsal pons, which projects throughout the entire neocortex, thalamus, limbic system, cerebellum, and spinal cord.
  • Function: Regulates vigilance, sustained attention, fight-or-flight sympathetic arousal, and sleep-wake transitions. Firing rates are highest during novel or threatening stimuli and quiescent during REM sleep.
  • Adrenergic Receptors: Metabotropic receptors divided into $\alpha_1$ ($G_q$), $\alpha_2$ ($G_i$ autoreceptors that suppress NE exocytosis), and $\beta_1, \beta_2, \beta_3$ ($G_s$). Centrally acting $\beta$-blockers (e.g., propranolol) attenuate peripheral autonomic arousal in performance anxiety and have been studied, with mixed results, as a way to weaken the reconsolidation of traumatic emotional memories.
• Epinephrine (Adrenaline): Synthesized primarily in the adrenal medulla (chromaffin cells) under direct preganglionic sympathetic stimulation, operating predominantly as a systemic circulating hormone rather than a central neurotransmitter.

Indolamines: Serotonin (5-HT)

Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the essential dietary amino acid L-tryptophan:

$\text{L-Tryptophan} \xrightarrow[\text{(Rate-Limiting Step)}]{+ \text{ Tryptophan Hydroxylase (TPH)}} \text{5-HTP} \xrightarrow{+ \text{ AADC}} \text{5-HT}$

• Anatomy: Central serotonergic neurons are concentrated almost exclusively within the brainstem Raphe nuclei (dorsal and median raphe in the midbrain and pons), which send diffuse projections throughout the forebrain, limbic system, and dorsal horns of the spinal cord.
• Receptors: At least 14 distinct receptor subtypes grouped into seven families ($5\text{-HT}_1$ through $5\text{-HT}_7$). All are metabotropic GPCRs except the $5\text{-HT}_3$ receptor, which is an ionotropic ligand-gated cation channel (antagonized by the antiemetic ondansetron). The $5\text{-HT}_{2A}$ receptor ($G_q$) is the primary site of action for classic hallucinogens (LSD, psilocybin, mescaline).
• Functions and Inactivation: Modulates mood, affect, anxiety, sleep-wake cycles, appetite (satiety), thermal regulation, and pain transmission. Inactivated by the serotonin transporter (SERT) and degraded intracellularly by monoamine oxidase A (MAO-A).

3. Amino Acid Neurotransmitters: Glutamate and GABA

Amino acids are the workhorses of fast synaptic transmission, responsible for >90% of synaptic traffic in the CNS.

Glutamate

Glutamate is the universal excitatory neurotransmitter in the mammalian central nervous system, synthesized from glutamine by the mitochondrial enzyme glutaminase.

                               [ GLUTAMATE RECEPTORS ]
                                          │
             ┌────────────────────────────┴────────────────────────────┐
             ▼                                                         ▼
  [ IONOTROPIC RECEPTORS ]                                  [ METABOTROPIC (mGluRs) ]
  ├── AMPA Receptor: Fast Na+ influx                        ├── Group I (mGluR1,5): Gq coupled
  ├── Kainate Receptor: Modulatory cation channel           └── Group II/III: Gi coupled (autoreceptors)
  └── NMDA Receptor: Molecular Coincidence Detector
      - Highly permeable to Ca2+ and Na+
      - Blocked at rest by extracellular Mg2+ ion
      - Requires Depolarization + Glutamate + Glycine
      - Cellular substrate of Long-Term Potentiation (LTP)

• The NMDA Receptor as a Coincidence Detector:
  • At resting membrane potentials (-70 mV), the NMDA receptor pore is physically obstructed by an extracellular magnesium ion ($Mg^{2+}$) held in place by intracellular negative charge.
  • Opening the channel requires two simultaneous conditions: (1) Glutamate binding (along with co-agonist glycine or D-serine), and (2) Membrane depolarization (typically provided by adjacent AMPA receptor activation), which electrostatically expels the $Mg^{2+}$ plug from the pore.
  • Once unblocked, NMDA channels permit robust $Ca^{2+}$ influx along with $Na^+$. This intracellular $Ca^{2+}$ surge acts as a second messenger, activating calcium/calmodulin-dependent protein kinase II (CaMKII), which inserts additional AMPA receptors into the postsynaptic density, establishing Long-Term Potentiation (LTP)—the cellular foundation of learning and memory.
• Excitotoxicity: Impaired astrocytic glutamate uptake or prolonged ischemic insults (e.g., stroke) result in massive, pathological accumulation of glutamate in the cleft. Uncontrolled NMDA activation drives excessive, lethal $Ca^{2+}$ influx, activating intracellular proteases (calpains), endonucleases, and phospholipases that dismantle the neuron, resulting in apoptotic and necrotic cell death.

GABA ($\gamma$-Aminobutyric Acid)

GABA is the primary inhibitory neurotransmitter in the mature mammalian brain, synthesized directly from glutamate by the enzyme glutamic acid decarboxylase (GAD), which requires the cofactor pyridoxal phosphate (Vitamin $B_6$).

• $\text{GABA}_A$ Receptor: A heteropentameric ionotropic ligand-gated chloride ($Cl^-$) channel. Channel opening allows $Cl^-$ to flow inward down its chemical gradient, hyperpolarizing the membrane or holding it below threshold (shunting inhibition). The $\text{GABA}_A$ macromolecular complex contains distinct allosteric modulatory binding sites:
  • Benzodiazepines (e.g., diazepam, lorazepam): Bind to a distinct allosteric pocket between $\alpha$ and $\gamma$ subunits, increasing the frequency of channel opening in the presence of GABA.
  • Barbiturates (e.g., phenobarbital, thiopental): Bind to an alternate site, increasing the duration of channel opening; at high concentrations, barbiturates can open the pore directly in the absence of GABA, accounting for their narrow therapeutic window and fatal overdose potential via respiratory depression.
  • Ethanol: Allosterically enhances $\text{GABA}_A$ chloride conductance while simultaneously inhibiting NMDA glutamate receptors.
• $\text{GABA}_B$ Receptor: A heterodimeric metabotropic GPCR coupled to $G_i/G_o$. Stimulates opening of inward-rectifying potassium channels ($K^+$ efflux) and inhibits presynaptic voltage-gated calcium channels, generating slow, prolonged inhibitory postsynaptic potentials. Selectively stimulated by the muscle relaxant baclofen.

4. Neuropeptides and Psychopharmacology

Neuropeptides are large polymers composed of 3 to 40 amino acids, synthesized in the soma, packaged into dense-core vesicles, and transported down the axon via fast axonal transport. They act at low concentrations with high affinity at metabotropic receptors, often co-released with small-molecule neurotransmitters:

• Endorphins and Enkephalins: Endogenous opioid peptides derived from precursor proteins (e.g., pro-opiomelanocortin / POMC). Bind to $\mu$, $\delta$, and $\kappa$ opioid GPCRs in the periaqueductal gray and dorsal horn to suppress pain transmission and activate dopamine release in the mesolimbic reward system by inhibiting GABAergic interneurons. Blocked by competitive opioid antagonists like naloxone (Narcan).
• Substance P: An 11-amino acid tachykinin peptide released by primary nociceptive C-fibers in the spinal dorsal horn, transmitting slow, burning pain sensations. Depleted by repeated exposure to capsaicin.

Psychopharmacological Classes and Synaptic Mechanisms